|
|
|
|
 |
 |
GlaxoSmithKline Press Releases |
 |
|
|
|
|
11th December, 2006
Trial data showed eltrombopag decreased bleeding episodes and improved platelet counts in patients with chronic idiopathic thrombocytopenic purpura
Trial data showed eltrombopag decreased bleeding episodes and improved platelet counts in patients with chronic idiopathic thrombocytopenic purpura
Results from short-term Phase II study demonstrated potential for eltrombopag to become first oral platelet growth factor
Issued — Monday 11th December 2006, London, UK - GlaxoSmithKline (GSK) today announced additional results from an international Phase II short-term, six-week study of its investigational non-peptide oral platelet growth factor, eltrombopag ...
|
8th December, 2006
GlaxoSmithKline to acquire Domantis for £230 million
GlaxoSmithKline to acquire Domantis for £230 million
GSK will further expand its biopharmaceuticals portfolio with acquisition of pioneering antibody technology
Issued — Friday 8 December 2006, London, UK— LSE Announcement
GlaxoSmithKline plc (GSK) today announces that it has entered into an agreement to acquire Domantis Ltd, a leader in developing the next generation of antibody therapies, for ₤230 million (US$454 million) in cash ...
|
6th December, 2006
Novel oral platelet growth factor, eltrombopag, to be evaluated in long term ITP study
Novel oral platelet growth factor, eltrombopag, to be evaluated in long term ITP study
Global trial initiated to investigate potential benefits in the use of eltrombopag for up to six months in chronic idiopathic thrombocytopenic purpura patients
Issued – Wednesday 6 December 2006, London, UK- GlaxoSmithKline plc today announced the initiation of the first global randomized, double-blind and placebo-controlled Phase III trial that will assess the safety, efficacy and tolerability of eltrombopag in a long-term treatment setting (six months) in previously treated patients with chronic idiopathic thrombocytopenic purpura (ITP) ...
|
4th December, 2006
Landmark study shows Avandia® is more effective than metformin or a sulphonylurea in long-term blood sugar control in type 2 diabetes
Landmark study shows Avandia® is more effective than metformin or a sulphonylurea in long-term blood sugar control in type 2 diabetes
Avandia reduces risk of monotherapy failure at five years
Embargoed until Monday 4 December 2006 - LSE announcement
14.30 London, 09.30 Philadelphia, 16.30 Cape Town - Results from ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial treatment with Avandia® (rosiglitazone maleate) reduced the risk of monotherapy failure in people with type 2 diabetes by 32 percent compared to metformin (p<0.001), and 63 percent compared to glyburide (p<0.001) at five years ...
|
1st December, 2006
Hycamtin® indication expanded to include treatment of cervical cancer in combination with chemotherapy
Hycamtin® indication expanded to include treatment of cervical cancer in combination with chemotherapy
Not for distribution to US Media
Of more than 40 regimens investigated1 Hycamtin® is the first to provide additional survival benefit beyond the current standard treatment
Issued — Friday 1 December 2006, London, UK - GlaxoSmithKline plc announced today that the European Medicines Agency (EMEA) has granted Marketing Authorisation for Hycamtin (topotecan HCl) in combination with cisplatin, for the treatment of patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease ...
|
29th November, 2006
Bill Louv appointed Senior Vice President, Information Technology; Ford Calhoun to retire from GSK
Bill Louv appointed Senior Vice President, Information Technology; Ford Calhoun to retire from GSK
Bill Louv has been appointed Senior Vice President, Information Technology, GlaxoSmithKline, following the retirement of Ford Calhoun at the end of January 2007 ...
|
29th November, 2006
GlaxoSmithKline welcomes decision by GAVI Alliance to support introduction of new vaccines against rotavirus and pneumococcal disease
GlaxoSmithKline welcomes decision by GAVI Alliance to support introduction of new vaccines against rotavirus and pneumococcal disease
Issued – Wednesday 29 November 2006, Rixensart, Belgium -Following the announcement by the GAVI Alliance today to commit funds to purchase new vaccines against rotavirus and pneumococcal diseases, Jean Stephenne, President and General Manager of GSK Biologicals, said:
“GAVI’s decision today to support the introduction of new vaccines against pneumococcal and rotavirus diseases is another advance for global health ...
|
20th November, 2006
GSK to supply and store H5N1 vaccine products for US flu pandemic stockpiling
GSK to supply and store H5N1 vaccine products for US flu pandemic stockpiling
GlaxoSmithKline awarded HHS contract
Philadelphia, PA, November 20, 2006–– GlaxoSmithKline (NYSE:GSK), one of the world’s largest vaccine manufacturers, today announced it has been awarded a contract to supply pre-pandemic vaccines to the US strategic national stockpile ...
|
15th November, 2006
GlaxoSmithKline and NeuroSearch expand the scope of strategic alliance
GlaxoSmithKline and NeuroSearch expand the scope of strategic alliance
Issued — Wednesday 15 November 2006, London, UK & Copenhagen, Denmark
GlaxoSmithKline (GSK) and NeuroSearch have agreed to expand the scope of the current 5-year strategic alliance within CNS and ion channel drug discovery and development:
1 ...
|
15th November, 2006
National survey reveals striking lack of understanding about common, life-threatening lung disease that affects millions
National survey reveals striking lack of understanding about common, life-threatening lung disease that affects millions
FOR IMMEDIATE RELEASE
Among other common chronic diseases only 4% of Americans cite COPD as condition they are most concerned about
Research Triangle Park, NC, November 15, 2006 — Results of a new survey conducted among more than 1,000 Americans age 45 and older reveal that most adults are not concerned about Chronic Obstructive Pulmonary Disease (COPD), a lung disease that is the fourth leading cause of death in the U.S ...
|
|
|
|
« Previous 10 Next 10 » |
|
|
|
|
